Table 3.
Association of analyzed genotypes with risk of critical COVID-19 disease.
| Gene | SNP | Genotype | Noncritical, n = 453 (%) | Critical, n = 193 (%) | Genetic Model | Unadjusted OR (95% CI) | p | Adjusted OR (95% CI) | p |
|---|---|---|---|---|---|---|---|---|---|
| GC | rs59241277 | AA AG GG |
363 (80.1) 86 (19.0) 4 (0.9) |
174 (90.2) 18 (9.3) 1 (0.5) |
AA vs. AG + GG | 0.47 (0.28–0.77) |
0.003 | 0.43 (0.24–0.77) |
0.005 |
| rs113574864 | CC CT TT |
350 (77.3) 96 (21.2) 7 (1.5) |
168 (87.0) 23 (11.9) 2 (1.1) |
CC vs. CT + TT | 0.47 (0.29–078) |
0.003 | 0.43 (0.24–0.78) |
0.005 | |
| rs182901986 | GG GA AA |
354 (78.1) 93 (20.5) 6 (1.3) |
171 (88.6) 20 (10.4) 2 (1.0) |
GG vs. GA + AA | 0.50 (0.31–0.80) |
0.003 | 0.49 (0.29–0.84) |
0.01 | |
| rs60349934 | TT TC CC |
359 (79.2) 91 (20.1) 3 (0.7) |
170 (88.1) 22 (11.4) 1 (0.5) |
TT vs. TC + CC | 0.55 (0.34–0.87) |
0.011 | 0.50 (0.28–0.86) |
0.01 | |
| rs113876500 | GG GT TT |
350 (77.3) 96 (21.2) 7 (1.5) |
168 (87.1) 23 (11.9) 2 (1.0) |
GG vs. GT + TT | 0.54 (0.35–0.84) |
0.006 | 0.53 (0.31–0.88) |
0.02 | |
| NADSYN1 | rs4944076 | AA AG GG |
148 (32.7) 198 (43.7) 107 (23.6) |
78 (40.4) 93 (48.2) 22 (11.4) |
AA vs. AG + GG | 0.66 (0.51–0.84) |
0.001 | 0.66 (0.49–0.90) |
0.008 |
| rs4944997 | GG GA AA |
144 (31.8) 199 (43.9) 110 (24.3) |
73 (37.8) 95 (49.2) 25 (13.0) |
GG vs. GA + AA | 0.69 (0.54–0.89) |
0.004 | 0.69 (0.51–0.93) |
0.02 | |
| rs4944998 | GG GC CC |
144 (31.8) 200 (44.2) 109 (24.1) |
73 (37.8) 95 (49.2) 25 (13.0) |
GG vs. GC + CC | 0.70 (0.55–0.89) |
0.004 | 0.70 (0.51–0.94) |
0.02 | |
| rs4944979 | GG GT TT |
146 (32.2) 197 (43.5) 110 (24.3) |
74 (38.3) 94 (48.7) 25 (13.0) |
GG vs. GT + TT | 0.69 (0.54–0.89) |
0.004 | 0.70 (0.52–0.94) |
0.02 | |
| rs10898210 | AA AG GG |
157 (34.7) 196 (45.2) 100 (22.1) |
85 (44.0) 87 (45.1) 21 (10.9) |
AA vs. AG + GG | 0.64 (0.50–0.82) |
0.0005 | 0.67 (0.50–0.90) |
0.009 | |
| VDR | rs11574018 | TT TC CC |
438 (96.7) 15 (3.3) 0 (0.0) |
192 (99.5) 1 (0.5) 0 (0.0) |
TT vs. TC + CC | 0.15 (0.02–1.17) |
0.051 | 0.10 (0.01–0.86) |
0.04 |
| rs11574024 | GG GT TT |
440 (97.1) 13 (2.9) 0 (0.0) |
190 (98.4) 3 (1.6) 0 (0.0) |
GG vs. GT + TT | 0.53 (0.15–1.89) |
0.328 | 0.20 (0.04–0.91) |
0.04 | |
| rs116886958 | CC CA AA |
428 (94.5) 25 (5.5) 0 (0.0) |
187 (96.9) 6 (3.1) 0 (0.0) |
CC vs. CA + AA | 0.55 (0.22–1.36) |
0.195 | 0.37 (0.13–1.04) |
0.06 | |
| rs10875694 | TT TA AA |
359 (79.2) 90 (19.9) 4 (0.9) |
158 (81.9) 32 (16.6) 3 (1.6) |
TT vs. TA + AA | 0.90 (0.60–1.33) |
0.602 | 0.63 (0.13–1.02) |
0.06 | |
| rs2239181 | AA AC CC |
429 (94.7) 24 (5.3) 0 (0.0) |
176 (91.2) 15 (7.8) 2 (1.0) |
AA + AC vs. CC | 1.00 (0.71–1.41) |
0.996 | 1.44 (0.95–2.18) |
0.08 | |
| CYP2R1 | rs11023373 | GG GC CC |
426 (94.0) 23 (5.1) 4 (0.9) |
188 (97.4) 5 (2.6) 0 (0.0) |
GG vs. GC + CC | 0.37 (0.14–0.95) |
0.034 | 0.39 (0.13–1.15) |
0.09 |
| rs11023374 | TT TC CC |
284 (62.7) 147 (32.5) 22 (4.9) |
130 (67.4) 55 (28.5) 8 (4.1) |
TT vs. TC + CC | 0.84 (0.62–1.14) |
0.271 | 0.73 (0.51–1.05) |
0.09 | |
| rs10500804 | TT TG GG |
165 (36.4) 209 (46.1) 79 (17.4) |
78 (40.4) 83 (43.0) 32 (16.6) |
TT vs. TG + GG | 0.90 (0.70–1.15) |
0.415 | 0.83 (0.61–1.11) |
0.22 | |
| rs1993116 | GG GA AA |
192 (42.4) 205 (45.3) 56 (12.4) |
75 (38.9) 91 (47.2) 27 (14.0) |
GG + GA vs. AA | 1.11 (0.87–1.43) |
0.377 | 1.24 (0.92–1.69) |
0.15 | |
| rs7935792 | AA AC CC |
362 (79.9) 84 (18.5) 7 (1.5) |
157 (81.3) 33 (17.1) 3 (1.6) |
AA vs. AC + CC | 0.92 (0.62–1.37) |
0.703 | 1.00 (0.61–1.65) |
0.99 |
An additive (dominant) genetic model was applied for the genetic model where the homozygous genotype of the more frequent allele was compared with the heterozygous genotype and homozygous genotype of the less frequent allele. Adjusted for age, sex, population stratification; OR = odds ratio; SNP = single-nucleotide polymorphism. Data are presented as frequencies (%) and OR (95% CI); p < 0.05 considered significant (shown in boldface).